Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies-Reference-Cited by-同舟云学术

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies

Published:2017-09-16 Issue:55 Volume:8 Page:93785-93799
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Li Jun¹²,Kumar Priyank¹,Anreddy Nagaraju¹,Zhang Yun-Kai¹,Wang Yi-Jun¹,Chen Yanglu¹³,Talele Tanaji T.¹,Gupta Kanav¹⁴,Trombetta Louis D.¹,Chen Zhe-Sheng¹

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, New York, 11439, USA

2. Department of Otolaryngology-Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

3. Department of Chemistry, Princeton University, Princeton, NJ, 08544, USA

4. Jericho High School, Jericho, NY, 11753, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape;Expert Review of Clinical Pharmacology;2023-02-01

2. MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study;Acta Pharmaceutica Sinica B;2021-12

3. Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8+ T Cells;Vaccines;2021-11-08

4. ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates;Journal of Evidence-Based Medicine;2021-08-13

5. Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model;Frontiers in Cell and Developmental Biology;2021-03-22